Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Integra Lifesciences Holdings (IART) Gross Margin (2016 - 2026)

Integra Lifesciences Holdings' Gross Margin history spans 17 years, with the latest figure at 50.78% for Q4 2025.

  • On a quarterly basis, Gross Margin fell 549.0% to 50.78% in Q4 2025 year-over-year; TTM through Dec 2025 was 50.86%, a 391.0% decrease, with the full-year FY2025 number at 50.86%, down 391.0% from a year prior.
  • Gross Margin hit 50.78% in Q4 2025 for Integra Lifesciences Holdings, down from 51.48% in the prior quarter.
  • Over the last five years, Gross Margin for IART hit a ceiling of 62.83% in Q4 2022 and a floor of 50.37% in Q2 2025.
  • Historically, Gross Margin has averaged 57.3% across 5 years, with a median of 57.07% in 2023.
  • Biggest five-year swings in Gross Margin: surged 265bps in 2022 and later plummeted -840bps in 2023.
  • Tracing IART's Gross Margin over 5 years: stood at 61.47% in 2021, then grew by 2bps to 62.83% in 2022, then dropped by -9bps to 57.05% in 2023, then fell by -1bps to 56.27% in 2024, then fell by -10bps to 50.78% in 2025.
  • Business Quant data shows Gross Margin for IART at 50.78% in Q4 2025, 51.48% in Q3 2025, and 50.37% in Q2 2025.